Jeanine Kehl
study nurse
Medizinische Onkologie und Hämatologie · Dept. I
BMS CA 209-577
Dec 31, 2099Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (Phase I)
Clinical Studies - Dec 31, 2099 - Aug 9, 2019
Automatically Closed
Project leader: Hess Dagmar
Members: Kehl Jeanine, Müller Fiona
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The DANTE Trial A Trial of AIO in collaboration with SAKK
Apr 17, 2024
Clinical Studies - Apr 17, 2024 - Dec 31, 2028
Ongoing
Project leader: Horber Daniel
Members: Müller Fiona, Kehl Jeanine
A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
Dec 21, 2023
Clinical Studies - Dec 21, 2023 - Dec 31, 2027
Ongoing
Project leader: Jörger Markus
Members: Quinter Janine, Kehl Jeanine
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA
Apr 26, 2023Die Studie richtet sich an Personen, die an frühem HER2-negativem Brustkrebs leiden und ein hohes Rückfallrisiko nach medikamentöser Vorbehandlung und Operation aufweisen. In dieser Studie erhalten die Teilnehmenden entweder das Medikament mit dem Wi...
Clinical Studies - Apr 26, 2023 - Dec 31, 2099
Ongoing
Project leader: Huober Jens
Members: Quinter Janine, Kehl Jeanine
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear mainte-nance in patients with newly diagnosed Acute Myeloid Leu-kemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Oct 13, 2021Das Ziel dieser Studie ist es, die Therapie einer akuten myeloischen Leukämie (AML) oder eines myelodysplastischen Syndroms mit erhöhter Anzahl an Leukämiezellen (MDS-EB2) zu verbessern. Wir möchten nun die Wirksamkeit und Sicherheit von Gilteritinib...
Clinical Studies - Oct 13, 2021 - Dec 31, 2099
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Dec 18, 2019IDH1 or IDH2 mutations are each found in about 10% of AML – and specific inhibitors are approved or in development in this indication. The primary objective of this study is to compare event-free survival (EFS) between ivosidenib/enasidenib and pl...
Clinical Studies - Dec 18, 2019 - Dec 31, 2099
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine
A randomized trial assessing the role of arsenic
Jul 15, 2008Etude randomisée portant sur une désescalade thérapeutique utilisant une chimiothérapie de consolidation où l’Aracytine serait remplacée chez des patients par l’ATRA ou par le trixoyde d’arsenic (Trisenox®) dans le but de réduire la mortalité et la m...
Clinical Studies - Jul 15, 2008 - Sep 15, 2011
Automatically Closed
Project leader: Hitz Felicitas
Members: Kehl Jeanine
E-MOSAIC: A multicentre randomised controlled trial of longitudinal electronic monitoring of symptoms and syndromes associated with advanced cancer in patients treated with chemotherapy in palliative intention
May 27, 2007RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer receiving palliative c...
Clinical Studies - May 27, 2007 - Mar 31, 2012
Completed
Project leader: Strasser Florian
Members: Linder Susanne, Blum David, Kehl Jeanine
A randomized trial of axillary dissection versus no axillary dissection for patients with clinically node negative breast cancer and micrometastases in the sentinel node
Mar 3, 2003Axillary lymph nodes are often metastatic sites of primary breast cancer and are a major prognostic factor. No reliable non-invasive technique is available for detection of lymph node metastases. In most cases, Level I nodes (below pectoralis minor)...
Clinical Studies - Mar 3, 2003 - Feb 28, 2010
Automatically Closed
Members: Kehl Jeanine